Binding bids for Merck KGaA's generics drugs unit, which analysts expect to fetch at least $6 billion, are due in by the end of April, people familiar with the situation said on Wednesday.
Shortlisted bidders still in the running for the business include rival generic drugmakers Teva of Israel, Iceland's Actavis and U.S.-based Mylan Laboratories sources said.
A private equity consortium grouping Bain Capital and Apax Partners is also through, along with a second one involving CVC Capital Partners and India's Aurobindo Pharma they added.
More
No comments:
Post a Comment